NASDAQ · BCYC
Bicycle Therapeutics plc
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for BCYC has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Dec 2026 | $-0.31 | $0.28 | $-0.66 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Fintel · Zacks · The Motley Fool- RTTNews · Oct 29, 3:18 PM EDTBicycle Therapeutics Reports Q3 Results; Nuzefatide Updates Expected In 2027(RTTNews) – Bicycle Therapeutics plc (BCYC) reported third-quarter 2026 financial results and highlighted pipeline progress, including FDA Orphan Drug Designation for its investigational pancreatic cancer candidate, nuzefatide pevedotin.
- Fintel · Oct 29, 12:42 PM EDTBicycle Therapeutics plc Reports Third Quarter 2026 Financial ResultsBicycle Therapeutics plc reported its financial results for the third quarter ended September 30, 2026, and provided recent corporate updates. The company reported cash and cash equivalents of $469.9 million as of September 30, 2026, compared to $628.1 million as of December 31,
- RTTNews · Jul 31, 2:56 AM EDTBicycle Therapeutics Q2 Loss Narrows; Advances Cancer Pipeline(RTTNews) – Bicycle Therapeutics (BCYC) reported financial results for the second quarter that ended on June 30, 2026, reflecting a narrower net loss and provided updates on the progress of its oncology pipeline.
- Zacks · Jul 3, 5:05 AM EDTTarsus Pharmaceuticals (TARS) Moves 7.5% Higher: Will This Strength Last?Tarsus Pharmaceuticals (TARS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- RTTNews · Jun 25, 3:45 AM EDTKymera Appoints Felix Baker As Board Chairman, Succeeds Bruce Booth(RTTNews) – Kymera Therapeutics, Inc. (KYMR), a clinical-stage biopharmaceutical company, announced the appointment of Felix J. Baker as Chairman of the Board of Directors. He succeeds Bruce Booth, who has served as Chairman of Kymera since 2016 and will remain on the Board as an
- RTTNews · Apr 21, 6:41 AM EDTBicycle Therapeutics Highlights On Nuzefatide Pevedotin And EphA2 Pipeline At AACR Meet 2026(RTTNews) – Bicycle Therapeutics plc (BCYC), a clinical-stage pharmaceutical company, announced updates from its EphA2 pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2026.
- Zacks · Apr 16, 9:55 AM EDTWall Street Analysts Believe Bicycle Therapeutics (BCYC) Could Rally 137.88%: Here's is How to TradeThe mean of analysts' price targets for Bicycle Therapeutics (BCYC) points to a 137.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- Zacks · Mar 24, 9:35 AM EDTAfter Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Bicycle Therapeutics (BCYC)Bicycle Therapeutics (BCYC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- Zacks · Mar 23, 9:35 AM EDTBicycle Therapeutics (BCYC) Loses 19.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerBicycle Therapeutics (BCYC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- Fintel · Nov 24, 7:04 PM ESTTruist Securities Initiates Coverage of Bicycle Therapeutics plc – Depositary Receipt (BCYC) with Hold RecommendationFintel reports that on November 24, 2025, Truist Securities initiated coverage of Bicycle Therapeutics plc – Depositary Receipt (NasdaqGS:BCYC) with a Hold recommendation. Analyst Price Forecast Suggests 255.06% Upside
- Fintel · Oct 31, 7:04 PM EDTCitizens Maintains Bicycle Therapeutics plc – Depositary Receipt (BCYC) Market Outperform RecommendationFintel reports that on October 31, 2025, Citizens maintained coverage of Bicycle Therapeutics plc – Depositary Receipt (NasdaqGS:BCYC) with a Market Outperform recommendation. Analyst Price Forecast Suggests 209.00% Upside
- The Motley Fool · Aug 8, 7:56 AM EDTBicycle (BCYC) Q2 Revenue Falls 69%Revenue (GAAP) for Q2 2025 was $2.92 million, falling sharply short of the $9.43 million analyst estimate.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Bicycle Therapeutics plc from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.